Shanghai – September 28, 2026 – Cooley advised SciBrunch Therapeutics (SciBrunch), a clinical-stage biotechnology company driven by iterative innovation in small molecule oncology therapeutics, on its exclusive global license agreement with Merck (New York Stock Exchange: MRK) for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor, which has now closed.

Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of $400 million and is eligible to receive payments associated with the achievement of certain milestones related to development, commercialization and other activities across multiple indications. The total potential aggregate value of the transaction, including the upfront payment, is $2.13 billion.

Lawyers Yiming Liu, Geoffrey Spolyar and Zack Gong led the Cooley team advising SciBrunch, with invaluable support from Shawn Yu, Aaron Pomeroy, David Burns, Julia Brinton, Zhijing Yu, Andrew Epstein, Karen Tsai, Monica Xu, Lunga Su, Snow Yang, Amanda Pacheco and Asako Kubota.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

Related Contacts

Yiming Liu
Partner in Charge – Shanghai
Shanghai
Geoffrey Spolyar
Partner
Boston
Zack Gong
Associate
Shanghai
Shawn Yu
Dr. Xiaozhen (Shawn) Yu
Partner
Washington, DC
Aaron Pomeroy
Partner
Colorado
David Burns
Special Counsel
Washington, DC
Julia R. Brinton
Special Counsel
Washington, DC
Zhijing Yu
Special Counsel
Singapore
Andrew Epstein
Special Counsel
Seattle
Karen Tsai
Special Counsel
Washington, DC
Monica Xu
Special Counsel
Shanghai
Lunga Su
Associate
Shanghai
Snow Yang
International Legal Project Manager
Shanghai
Amanda Pacheco
Associate
Palo Alto
Dr. Asako Kubota
Associate
Washington, DC

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.